BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Marcadia Biotech Initiates Phase 1 Clinical Trial of GLP-1/GIP Dual Agonist MAR701


2/17/2010 8:37:28 AM

INDIANAPOLIS, Feb. 17 /PRNewswire/ -- Marcadia Biotech Inc. today announced that it has initiated a Phase 1 clinical trial of MAR701, a novel dual agonist of the incretin hormone receptors for glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). Marcadia plans to initially develop this compound as a treatment for type 2 diabetes with once-weekly dosing. The Phase 1 trial will evaluate MAR701 in healthy volunteers at escalating dose levels.

MAR701 targets two peptide hormones that are elevated physiologically following a meal and pharmacologically by drugs in the DPP-4 inhibitor class, which are used to lower blood glucose. Drugs in the GLP-1 agonist class directly activate the GLP-1 receptor pathway to lower blood glucose and may also decrease body weight. Preclinical testing by Marcadia of MAR701 demonstrated significant reductions in blood glucose levels and body weight.

"In preclinical studies, we have seen that simultaneous activation of GLP-1 and GIP receptors produced additive efficacy with no apparent side effects," said Fritz French, Marcadia's chief executive officer. "This approach is not limited by endogenous levels of GIP and GLP-1, like DPP-4 inhibitors, and a dual agonist directly activates both receptors, unlike GLP-1 receptor agonists. We believe this holds significant promise for treating type 2 diabetes, and potentially obesity in the future."

MAR701 originated through Marcadia's discovery collaboration with the laboratory of Dr. Richard DiMarchi, the Linda & Jack Gill Chair in Biomolecular Sciences and professor of chemistry at Indiana University Bloomington. This collaboration leverages the therapeutic experience in diabetes and obesity of both groups with the unique peptide chemistry capabilities of the DiMarchi Lab.

About Marcadia Biotech

Marcadia Biotech is a biopharmaceutical company focused on developing a broad portfolio of drug candidates for treatment of diabetes and obesity. Using proprietary peptide chemistry, Marcadia seeks to develop candidates with unprecedented performance in key metabolic hormone pathways. Separately, the company is also developing a set of novel peptides in collaboration with Merck & Co. and independently a glucagon analog for acute treatment of severe hypoglycemia. Founded in 2006, Marcadia is based in Carmel, Ind. For more information, visit http://www.marcadiabiotech.com.

Media Contact: Ian Stone Russo Partners, LLC (619) 528-2220 ian.stone@russopartnersllc.com SOURCE Marcadia Biotech Inc. RELATED LINKS http://www.marcadiabiotech.com


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->